Chronic kidney disease and bisphosphonate treatment: Are prescribing guidelines unnecessarily restrictive?

Postgraduate Medical Journal

Volumn 85, Issue 1004, 2009, Pages 327-330

  Courtney, A E ^a   Maxwell, A P ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; LORON; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE KIDNEY TUBULE NECROSIS; BONE CANCER; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; NEPHROTIC SYNDROME; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; CHRONIC DISEASE; CREATININE; DIPHOSPHONATES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 67649742585     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.076356     Document Type: Review

References (23)

1. National Institute for Health and Clinical Excellence. Osteoporosis - secondary prevention. London: NICE, 2005: www.nice.org.uk/search/ guidancesearchresults. jsp?keywords=osteoporosis&searchType=guidance (accessed 24 Oct 2008).
2. British National Formulary. BNF 2008. London: British Medical Association, Royal Pharmaceutical Society of Great Britain. www.bnf.org/bnf/bnf/ 55/100042.htm (accessed 24 Oct 2008).
3. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007;20:186-190
4. Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003;14:570-576 (Pubitemid 36975556)
5. Medicines Compendium. http://emc.medicines.org.uk/ (accessed 24 Oct 2008).
6. Troehler U, Bonjour JP, Fleisch H. Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions. J Lab Clin Med 1985;106:23-29 (Pubitemid 16052001)
7. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172 (Pubitemid 32472629)
8. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679
9. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289 (Pubitemid 36714182)
10. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551-570 (Pubitemid 40994085)
11. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333:166-174
12. Miller PD. Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists. Curr Rheumatol Rep 2005;7:53-60.
13. Courtney AE, Leonard N, McCloskey MC, et al. Bisphosphonate prescribing in chronic kidney disease. J R Coll Physicians Edinb 2009;39:4-9.
14. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105-2115 (Pubitemid 41698774)
15. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-1393
16. Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005;3:5-12.
17. Mitchell DY, St Peter JV, Eusebio RA, et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000;49:215-222 (Pubitemid 30150982)
18. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
19. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483 (Pubitemid 43855050)
20. Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43:566-571 (Pubitemid 38298217)
21. Anon. NKF-K/DOQI Clinical Practice Guidelines. Am J Kidney Dis 2003;42(Suppl 3):S1-201.
22. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999;55:2141-2156 (Pubitemid 29256470)
23. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004;43:558-565 (Pubitemid 38298216)